TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene, polyglycolic acid, and polylactic-co-glycolic acid designed to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. TELA Bio, Inc. was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.…
TELA Bio Inc (TELA) (Q3 2026) Earnings Call Highlights: Cost Cuts, Leora Clearance and a Reset ...
TELA Bio (NASDAQ: TELA) is listed on Nasdaq, where its shares trade in USD. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 218 employees.
The shares were at 0.6885 USD on 20 November 2026, down 41.7% over 52 weeks. Its 52-week range is 0.5010 USD to 1.500 USD: the price is 54.1% below the high and 37.4% above the low.
Its market capitalisation is 31.11M USD.
TELA Bio reports an operating margin of -40.5% and revenue down 8.4% year over year.
Its debt exceeds its cash by 35.38M USD, a debt-to-equity ratio of 8.90. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. 3 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 2.000 USD is 190.5% above the current price. The next earnings report is expected on 23 March 2027.